[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-400652-105":59,"doc-detail-400652-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-options-of-hiv-pre-exposure-prophylaxis-prep-for-adolescents","Current Options of HIV Pre-Exposure Prophylaxis (PrEP) for Adolescents","","A clinical overview explains pre-exposure prophylaxis (PrEP) for adolescents, focusing on current and emerging medication options. The material defines PrEP and compares oral PrEP, injection-based long-acting options, and on-demand strategies, including key effectiveness and eligibility considerations. It outlines an approach to HIV testing, referral, initiation, and PrEP management, and highlights baseline laboratory requirements and practical adverse-event monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-options-of-hiv-pre-exposure-prophylaxis-prep-for-adolescents/400652/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-options-of-hiv-pre-exposure-prophylaxis-prep-for-adolescents/400652.png","ImageObject",300,407,{"name":92,"@type":93},"Damian","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is PrEP and how does it prevent HIV acquisition?","Question",{"text":112,"@type":113},"PrEP uses antiretroviral drugs in people with negative HIV status to prevent HIV acquisition. It can be oral, injectional, or vaginal (vaginal not approved in the US), and it works when taken before exposure and, for oral on-demand strategies, before and after sexual exposure.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which oral PrEP options are discussed for adolescents?",{"text":117,"@type":113},"Truvada (FTC/TDF) is FDA-approved in 2012 and expanded to adolescents in 2018, used as a daily tablet for people at risk through sex or IVDU with weight ≥35 kg, and can be used on demand by MSM. Descovy (FTC/TAF) is FDA-approved in 2019 for adolescents and is used as a daily tablet for sexually active men at risk with weight ≥35 kg, but cannot be used in women at risk through receptive vaginal sex.",{"name":119,"@type":110,"acceptedAnswer":120},"What baseline laboratory testing is required before starting PrEP?",{"text":121,"@type":113},"Required testing includes an HIV Ag/Ab test (preferably lab-based) and HIV RNA for injectable PrEP to confirm negative status. Kidney function is required with creatinine clearance thresholds for FTC/TDF (>60 mL/min) and FTC/TAF (>30 mL/min). Hepatitis B screening (for FTC/TAF and FTC/TDF), lipid profile for FTC/TAF, and STI tests for chlamydia, gonorrhea, and syphilis are also included for indicated populations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},400652,1790642517,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},137451208677,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Can I Protect my Teen from HIV?  \nCurrent Options of HIV Pre-Exposure Prophylaxis (PrEP) for Adolescents  \nNatella Rakhmanina, MD, PhD  \nProfessor of Pediatrics  \nThe George Washington University  \nAssociate Chief, Division of Infectious Diseases Director, HIV Prevention and Treatment Services Children’s National Hospital  \nLearning Goals  \n1. Describe current and future medications for the Pre-Exposure Prophylaxis ( PrEP ) in adolescents  \n2. Discuss algorithm for the HIV testing, PrEP referrals, initiation and management  \n3. Describe national and regional epidemiology of HIV and PrEP use in adolescents  \n4. Identify optimal approach to integrating PrEP with the prevention of other sexually transmitted infections (STIs) such as DoxyPEP  \n2  \nWhat is PrEP?  \nPrEP  \n• Use of antiretroviral drugs by a person with negative HIV status to prevent acquisition of HIV  \n• PrEP can be oral, injectional & vaginal* (*not approved for use in the US)  \n• Injectional and vaginal PrEP are long-acting  \n• PrEP works when taken either before the potential exposure (oral or injectional) or before and after sexual exposure (oral PrEP on demand)  \n• Oral and injectional PrEP reduce the risk of acquiring HIV from sex by ~99% when taken as prescribed  \n• Oral PrEP reduces the risk of acquiring HIV through intravenous drug use (IVDU) by ≥74% when taken as prescribed  \nOral PrEP  \n• Truvada (emtricitabine/tenofovirdisoproxil fumarate, FTC/TDF, generic)  \n• FDA approved in 2012, expanded to adolescents in 2018  \n• oral daily tablet for all people at risk for HIV through sex or IVDU use and with weight ≥35 kg  \n• can be used on demand by MSM  \n▪ 7 days of daily oral PrEP for receptive anal sex protection  \n▪ 21 days of daily oral PrEPs use for receptive vaginal sex & IVDU protection • Descovy (emtricitabine/tenofovir alafenamide, FTC/TAF, generic in 2026)  \n• FDA approved in 2019 including adolescents  \n• oral daily tablet for sexually active men at risk of getting HIV and with weight ≥35 kg  \n• cannot be used in women who are at risk for HIV through receptive vaginal sex  \nFTC/TAF  \nFTC/TDF  \nOn Demand PrEP, FTC/TDF  \n[https://brownmedpedsresidency.org/on](https://brownmedpedsresidency.org/on)demand-prep/  \nMSM Only  \n• When having sex again while doing 2-1-1 then keep taking 1 pill daily until 48 hrs after last sex  \n• When completed 2-1-1 and then having sex again and it is  \n\u003C 7 days after completing 2-1-1 then resume 1 pill daily until 48 hrs after last sex  \n> 7 days after completing 2-1-1 then restart 2-1-1 from beginning  \nClinical Considerations for PrEP  \n• Common adverse events (AEs) with oral PrEP:  \n▪ Headaches  \n▪ Nausea  \n▪ Abdominal pain  \n▪ Diarrhea  \n▪ Decreased renal function with TDF  \n▪ Decreased bone mineral density with prolonged use ofTDF  \n▪ Triglyceride elevation with use of TAF  \n▪ Weight gain with use ofTAF  \n• AEs typically mild short lasting and reversable  \n• HBV status is required!  \n• Common AEs with injectable PrEP:  \n▪ Injection site reactions-pain and swelling  \n▪ Subcutaneous nodules SQ LEN  \n• Low rates of discontinuation in clinical trials and observational cohort  \n• Narrow injection window  \n▪ LEN±2 weeks and CAB ±1 week  \n• Long pharmacokinetic tail requires discontinuation strategy  \n▪ Switch to oral PrEP with ongoing risk exposures  \n• Drug-drug interactions – LEN > CAB  \n7  \nKey Guidelines  \n• CDC Guidelines-Preexposure Prophylaxis for the Prevention of HIV infection in the United States-2021 Update. A clinical Practice Guideline. [https://stacks.cdc.gov/view/cdc/1](https://stacks.cdc.gov/view/cdc/1) 12360  \n• Patel RR, Hoover KW, Lale A, Cabrales J, Byrd KM, Kourtis AP. Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis  \n—United States, 2025. MMWR Morb Mortal Wkly Rep 2025;74:541–549.  \nBaseline Laboratory Testing PrEP  \nREQUIRED  \nHIV test (Ag/Ab test, preferably lab based), HIV RNA for injectable PrEP to confirm negative status  \nKidney function  \nF/TDF: Estimat","cbCaiu1A4udil8qt","https://ap.wps.com/l/cbCaiu1A4udil8qt","pdf",1024097,34,"English","# Learning Goals\n# What is PrEP?\n## Oral PrEP\n## On Demand PrEP\n## Injectable and Other Long-Acting Options\n# Clinical Considerations for PrEP\n# Key Guidelines\n# Baseline Laboratory Testing PrEP\n# Timing of HIV Tests","[{\"question\":\"What is PrEP and how does it prevent HIV acquisition?\",\"answer\":\"PrEP uses antiretroviral drugs in people with negative HIV status to prevent HIV acquisition. It can be oral, injectional, or vaginal (vaginal not approved in the US), and it works when taken before exposure and, for oral on-demand strategies, before and after sexual exposure.\"},{\"question\":\"Which oral PrEP options are discussed for adolescents?\",\"answer\":\"Truvada (FTC/TDF) is FDA-approved in 2012 and expanded to adolescents in 2018, used as a daily tablet for people at risk through sex or IVDU with weight ≥35 kg, and can be used on demand by MSM. Descovy (FTC/TAF) is FDA-approved in 2019 for adolescents and is used as a daily tablet for sexually active men at risk with weight ≥35 kg, but cannot be used in women at risk through receptive vaginal sex.\"},{\"question\":\"What baseline laboratory testing is required before starting PrEP?\",\"answer\":\"Required testing includes an HIV Ag/Ab test (preferably lab-based) and HIV RNA for injectable PrEP to confirm negative status. Kidney function is required with creatinine clearance thresholds for FTC/TDF (\\u003e60 mL/min) and FTC/TAF (\\u003e30 mL/min). Hepatitis B screening (for FTC/TAF and FTC/TDF), lipid profile for FTC/TAF, and STI tests for chlamydia, gonorrhea, and syphilis are also included for indicated populations.\"}]","Current Options of HIV Pre-Exposure Prophylaxis (PrEP) for Adolescents | PDF",1790512990,86]